An image purportedly showing an authentic 1950s advertisement was a fake, mimicking typical sexist advertising of the era.

Biktarvy continues to be a strong growth asset for Gilead, while Yeztugo’s launch rides an upward trajectory.

Gilead raised its previous guidance of $800 million in revenues from the long-acting PrEP injectable Yeztugo based on a ...

The drugmaker raised its estimate for 2026 sales of HIV ⁠prevention drug ⁠Yeztugo, which was launched in the U.S. last year, ...

Minnesota's Legislature is reckoning with 340B, a prescription medication discount program for nonprofit hospitals, for ...

Since his second term started, President Trump has introduced a flurry of initiatives aimed at taming the excesses of the pharmaceutical industry.

Some clinical trials aren't designed to answer scientific questions. They're designed to market drugs. In our recently ...

Use of Gilead Sciences' Yeztugo, a twice-yearly injection to prevent HIV infection, has climbed since its June launch, but ...

April 21 (Reuters) - The U.S. Food and Drug Administration has approved Merck's (MRK.N), opens new tab once-daily, oral, combination regimen for HIV infections, the drugmaker ‌said on Tuesday, giving ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. NAKURU, KENYA - 2026/03/26: A healthcare worker fills a syringe with a dose of lenacapavir, ...

Human immunodeficiency virus-1 (HIV) is one of the most challenging viruses for doctors to treat. Even with effective antiretroviral therapy, immune cells infected with HIV can hide and lie inactive ...

This is read by an automated voice. Please report any issues or inconsistencies here. Gilead’s lenacapavir could transform the fight against HIV — but only if millions more patients can get it. By ...